Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
VASC's Cash-to-Debt is ranked higher than
99% of the 288 Companies
in the Global Medical Devices industry.

( Industry Median: 2.45 vs. VASC: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
VASC' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.11  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.91
VASC's Equity-to-Asset is ranked higher than
96% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 0.62 vs. VASC: 0.91 )
Ranked among companies with meaningful Equity-to-Asset only.
VASC' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.34  Med: 0.87 Max: 0.96
Current: 0.91
0.34
0.96
Interest Coverage No Debt
VASC's Interest Coverage is ranked higher than
98% of the 226 Companies
in the Global Medical Devices industry.

( Industry Median: 93.54 vs. VASC: No Debt )
Ranked among companies with meaningful Interest Coverage only.
VASC' s Interest Coverage Range Over the Past 10 Years
Min: 48.63  Med: 1211.19 Max: No Debt
Current: No Debt
Piotroski F-Score: 6
Altman Z-Score: 43.82
Beneish M-Score: -2.21
WACC vs ROIC
10.33%
13.56%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 8.33
VASC's Operating Margin % is ranked higher than
67% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. VASC: 8.33 )
Ranked among companies with meaningful Operating Margin % only.
VASC' s Operating Margin % Range Over the Past 10 Years
Min: -8.18  Med: 13.25 Max: 17.33
Current: 8.33
-8.18
17.33
Net Margin % 7.57
VASC's Net Margin % is ranked higher than
73% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: 1.50 vs. VASC: 7.57 )
Ranked among companies with meaningful Net Margin % only.
VASC' s Net Margin % Range Over the Past 10 Years
Min: -8.15  Med: 10.08 Max: 27.25
Current: 7.57
-8.15
27.25
ROE % 9.26
VASC's ROE % is ranked higher than
70% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 2.08 vs. VASC: 9.26 )
Ranked among companies with meaningful ROE % only.
VASC' s ROE % Range Over the Past 10 Years
Min: -31.56  Med: 13.33 Max: 72.44
Current: 9.26
-31.56
72.44
ROA % 8.28
VASC's ROA % is ranked higher than
81% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 0.20 vs. VASC: 8.28 )
Ranked among companies with meaningful ROA % only.
VASC' s ROA % Range Over the Past 10 Years
Min: -16.48  Med: 11.29 Max: 42.87
Current: 8.28
-16.48
42.87
ROC (Joel Greenblatt) % 18.98
VASC's ROC (Joel Greenblatt) % is ranked higher than
67% of the 288 Companies
in the Global Medical Devices industry.

( Industry Median: 4.02 vs. VASC: 18.98 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
VASC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -28.47  Med: 39.66 Max: 56.54
Current: 18.98
-28.47
56.54
3-Year Revenue Growth Rate 10.90
VASC's 3-Year Revenue Growth Rate is ranked higher than
70% of the 227 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. VASC: 10.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
VASC' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 8.8  Med: 12.9 Max: 89.2
Current: 10.9
8.8
89.2
3-Year EBITDA Growth Rate -2.80
VASC's 3-Year EBITDA Growth Rate is ranked lower than
64% of the 199 Companies
in the Global Medical Devices industry.

( Industry Median: 5.60 vs. VASC: -2.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
VASC' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -63.8  Med: -5.15 Max: 265.1
Current: -2.8
-63.8
265.1
3-Year EPS without NRI Growth Rate -1.10
VASC's 3-Year EPS without NRI Growth Rate is ranked lower than
54% of the 197 Companies
in the Global Medical Devices industry.

( Industry Median: 3.40 vs. VASC: -1.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
VASC' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -67.2  Med: -14.65 Max: 22.1
Current: -1.1
-67.2
22.1
GuruFocus has detected 4 Warning Signs with Vascular Solutions Inc $VASC.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» VASC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

VASC Guru Trades in Q1 2016

Mairs and Power 75,553 sh (+8.16%)
Jim Simons 496,700 sh (+3.31%)
Chuck Royce Sold Out
Mario Gabelli 227,200 sh (-0.87%)
» More
Q2 2016

VASC Guru Trades in Q2 2016

Mairs and Power 75,653 sh (+0.13%)
Mario Gabelli 211,800 sh (-6.78%)
Jim Simons 442,700 sh (-10.87%)
» More
Q3 2016

VASC Guru Trades in Q3 2016

Mairs and Power 75,453 sh (-0.26%)
Mario Gabelli 208,300 sh (-1.65%)
Jim Simons 327,800 sh (-25.95%)
» More
Q4 2016

VASC Guru Trades in Q4 2016

Mario Gabelli 277,104 sh (+33.03%)
Mairs and Power 70,033 sh (-7.18%)
Jim Simons 243,300 sh (-25.78%)
» More
» Details

Insider Trades

Latest Guru Trades with VASC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 334510    SIC: 3845
Compare:NAS:MDXG, NAS:CSII, NAS:KTWO, NAS:CNMD, NAS:SPNC, NAS:OFIX, NYSE:ITGR, OTCPK:DGWPF, NAS:BABY, NAS:GNMK, NYSE:CRY, OTCPK:SHHPF, OTCPK:MZRTF, NAS:XENT, NAS:ARAY, NAS:INGN, NYSE:IVC, NAS:EXAC, OTCPK:IOBCF, NAS:ELOS » details
Traded in other countries:VA4.Germany,
Vascular Solutions Inc is a medical device company. It is engaged in providing solutions to interventional cardiologists and interventional radiologists.

Vascular Solutions Inc was incorporated in the state of Minnesota in December 1996. It is a medical device company, creates new minimally invasive medical devices, and delivers these products and related services to physicians through its direct domestic sales force and its international distribution network. The Company's products and services are divided into three categories: Catheter products; Hemostat products and Vein products and services. Catheter products consist principally of catheters used in minimally invasive medical procedures for the diagnosis or treatment of vascular conditions, such as the GuideLiner catheter used to access discrete regions of the coronary anatomy and the Pronto extraction catheters used in treating acute myocardial infarction. Hemostat products consist principally of blood clotting products, such as the D-Stat Dry hemostat, a topical thrombin-based pad with a bandage used to control surface bleeding, and the D-Stat Flowable, a thick yet flowable thrombin-based mixture for preventing bleeding in subcutaneous pockets. Vein products and services consist principally of the Vari-Lase endovenous laser, a laser console and procedure kit used for the treatment of varicose veins, and a reprocessing service for the ClosureFAST radiofrequency vein ablation catheter. The Company manufactures its products in its facilities located in the suburbs of Minneapolis, Minnesota and in the country of Ireland. The catheter manufacturing and packaging processes occur under a controlled clean room environment. It purchases components from various suppliers and rely on single sources for several parts of its products. It purchases its requirements for thrombin for use in manufacturing products sold in the U.S. under the Thrombin-JMI Supply Agreement with King. Its main competitors include: Medtronic, Boston Scientific, Covidien, Merit Medical, Marine Polymer Technologies, Cook Medical, Spectranetics, AngioDynamics and Terumo. The Company's products and services are regulated in the United States as medical devices by the FDA under the Federal Food, Drug and Cosmetic Act.

Guru Investment Theses on Vascular Solutions Inc

Mario Gabelli Comments on Vascular Solutions - Jan 31, 2017

Vascular Solutions, Inc. (NASDAQ:VASC) (0.4%) (VASC – $56.10 – NASDAQ) is a Minneapolis, Minnesota-based medical device company. VASC is engaged in the development and sale of medical diagnostic equipment specializing in the treatment and detection of cardiovascular related health issues. On December 2, 2016, the company agreed to a $56 cash per share merger with Teleflex Inc. which values VASC at $1 billion. The deal is subject to traditional regulatory and shareholder approvals and it should be completed in the first half of 2017.

From Mario Gabelli (Trades, Portfolio)'s ABC Fund fourth quarter 2016 commentary.

Check out Mario Gabelli latest stock trades

Mairs & Power Comments on Vascular Solutions - Dec 01, 2015

Vascular Solutions (NASDAQ:VASC) just continues to deliver strong results. The company is constantly developing strong new products for its sales force to push into the medical instrument market, and its core products have consistently shown strong growth.



From Mairs & Power Small Cap Fund third quarter 2015 commentary.



Check out Bill Frels latest stock trades

Top Ranked Articles about Vascular Solutions Inc

Mario Gabelli Comments on Vascular Solutions Guru stock highlight
Vascular Solutions, Inc. (NASDAQ:VASC) (0.4%) (VASC – $56.10 – NASDAQ) is a Minneapolis, Minnesota-based medical device company. VASC is engaged in the development and sale of medical diagnostic equipment specializing in the treatment and detection of cardiovascular related health issues. On December 2, 2016, the company agreed to a $56 cash per share merger with Teleflex Inc. which values VASC at $1 billion. The deal is subject to traditional regulatory and shareholder approvals and it should be completed in the first half of 2017. Read more...

Ratios

vs
industry
vs
history
PE Ratio 80.00
VASC's PE Ratio is ranked lower than
82% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 27.89 vs. VASC: 80.00 )
Ranked among companies with meaningful PE Ratio only.
VASC' s PE Ratio Range Over the Past 10 Years
Min: 5.09  Med: 26.29 Max: 447.5
Current: 80
5.09
447.5
Forward PE Ratio 38.02
VASC's Forward PE Ratio is ranked lower than
77% of the 57 Companies
in the Global Medical Devices industry.

( Industry Median: 23.04 vs. VASC: 38.02 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 80.00
VASC's PE Ratio without NRI is ranked lower than
83% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 28.39 vs. VASC: 80.00 )
Ranked among companies with meaningful PE Ratio without NRI only.
VASC' s PE Ratio without NRI Range Over the Past 10 Years
Min: 5.09  Med: 26.29 Max: 447.5
Current: 80
5.09
447.5
PB Ratio 6.89
VASC's PB Ratio is ranked lower than
79% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 3.35 vs. VASC: 6.89 )
Ranked among companies with meaningful PB Ratio only.
VASC' s PB Ratio Range Over the Past 10 Years
Min: 2.37  Med: 4.15 Max: 17.29
Current: 6.89
2.37
17.29
PS Ratio 6.16
VASC's PS Ratio is ranked lower than
72% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 3.31 vs. VASC: 6.16 )
Ranked among companies with meaningful PS Ratio only.
VASC' s PS Ratio Range Over the Past 10 Years
Min: 1.37  Med: 2.63 Max: 6.17
Current: 6.16
1.37
6.17
Price-to-Operating-Cash-Flow 77.24
VASC's Price-to-Operating-Cash-Flow is ranked lower than
91% of the 139 Companies
in the Global Medical Devices industry.

( Industry Median: 20.26 vs. VASC: 77.24 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
VASC' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.25  Med: 16.92 Max: 83.57
Current: 77.24
9.25
83.57
EV-to-EBIT 70.73
VASC's EV-to-EBIT is ranked lower than
87% of the 162 Companies
in the Global Medical Devices industry.

( Industry Median: 23.96 vs. VASC: 70.73 )
Ranked among companies with meaningful EV-to-EBIT only.
VASC' s EV-to-EBIT Range Over the Past 10 Years
Min: -106.9  Med: 16.1 Max: 183.7
Current: 70.73
-106.9
183.7
EV-to-EBITDA 47.36
VASC's EV-to-EBITDA is ranked lower than
84% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 17.54 vs. VASC: 47.36 )
Ranked among companies with meaningful EV-to-EBITDA only.
VASC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -424.7  Med: 13.4 Max: 61.3
Current: 47.36
-424.7
61.3
PEG Ratio 16.67
VASC's PEG Ratio is ranked lower than
87% of the 77 Companies
in the Global Medical Devices industry.

( Industry Median: 2.47 vs. VASC: 16.67 )
Ranked among companies with meaningful PEG Ratio only.
VASC' s PEG Ratio Range Over the Past 10 Years
Min: 0.45  Med: 2.65 Max: 4007
Current: 16.67
0.45
4007
Shiller PE Ratio 84.25
VASC's Shiller PE Ratio is ranked lower than
78% of the 50 Companies
in the Global Medical Devices industry.

( Industry Median: 54.18 vs. VASC: 84.25 )
Ranked among companies with meaningful Shiller PE Ratio only.
VASC' s Shiller PE Ratio Range Over the Past 10 Years
Min: 41.86  Med: 59.3 Max: 572.5
Current: 84.25
41.86
572.5
Current Ratio 6.37
VASC's Current Ratio is ranked higher than
89% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 2.33 vs. VASC: 6.37 )
Ranked among companies with meaningful Current Ratio only.
VASC' s Current Ratio Range Over the Past 10 Years
Min: 1.94  Med: 5.36 Max: 26.32
Current: 6.37
1.94
26.32
Quick Ratio 4.66
VASC's Quick Ratio is ranked higher than
86% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 1.67 vs. VASC: 4.66 )
Ranked among companies with meaningful Quick Ratio only.
VASC' s Quick Ratio Range Over the Past 10 Years
Min: 1.36  Med: 3.91 Max: 25.52
Current: 4.66
1.36
25.52
Days Inventory 151.53
VASC's Days Inventory is ranked lower than
62% of the 254 Companies
in the Global Medical Devices industry.

( Industry Median: 125.58 vs. VASC: 151.53 )
Ranked among companies with meaningful Days Inventory only.
VASC' s Days Inventory Range Over the Past 10 Years
Min: 130.39  Med: 149.76 Max: 182.03
Current: 151.53
130.39
182.03
Days Sales Outstanding 52.24
VASC's Days Sales Outstanding is ranked higher than
71% of the 240 Companies
in the Global Medical Devices industry.

( Industry Median: 66.89 vs. VASC: 52.24 )
Ranked among companies with meaningful Days Sales Outstanding only.
VASC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.41  Med: 50.18 Max: 54.98
Current: 52.24
47.41
54.98
Days Payable 27.06
VASC's Days Payable is ranked lower than
82% of the 227 Companies
in the Global Medical Devices industry.

( Industry Median: 57.49 vs. VASC: 27.06 )
Ranked among companies with meaningful Days Payable only.
VASC' s Days Payable Range Over the Past 10 Years
Min: 21.44  Med: 37.58 Max: 43.39
Current: 27.06
21.44
43.39

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.00
VASC's 3-Year Average Share Buyback Ratio is ranked higher than
60% of the 209 Companies
in the Global Medical Devices industry.

( Industry Median: -3.40 vs. VASC: -2.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
VASC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -53.7  Med: -2.7 Max: 0.4
Current: -2
-53.7
0.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 39.44
VASC's Price-to-Net-Cash is ranked lower than
82% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 15.26 vs. VASC: 39.44 )
Ranked among companies with meaningful Price-to-Net-Cash only.
VASC' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.56  Med: 24.36 Max: 539.5
Current: 39.44
0.56
539.5
Price-to-Net-Current-Asset-Value 12.96
VASC's Price-to-Net-Current-Asset-Value is ranked lower than
74% of the 217 Companies
in the Global Medical Devices industry.

( Industry Median: 6.50 vs. VASC: 12.96 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
VASC' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.48  Med: 6.9 Max: 28.94
Current: 12.96
0.48
28.94
Price-to-Tangible-Book 7.88
VASC's Price-to-Tangible-Book is ranked lower than
70% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 4.19 vs. VASC: 7.88 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
VASC' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.46  Med: 5.03 Max: 16.59
Current: 7.88
0.46
16.59
Price-to-Intrinsic-Value-Projected-FCF 4.87
VASC's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
78% of the 127 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. VASC: 4.87 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
VASC' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.38  Med: 2.3 Max: 130.33
Current: 4.87
1.38
130.33
Price-to-Median-PS-Value 2.34
VASC's Price-to-Median-PS-Value is ranked lower than
91% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 1.07 vs. VASC: 2.34 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
VASC' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.31  Med: 1.15 Max: 12.76
Current: 2.34
0.31
12.76
Price-to-Graham-Number 5.29
VASC's Price-to-Graham-Number is ranked lower than
78% of the 131 Companies
in the Global Medical Devices industry.

( Industry Median: 2.42 vs. VASC: 5.29 )
Ranked among companies with meaningful Price-to-Graham-Number only.
VASC' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.88  Med: 2.34 Max: 10.48
Current: 5.29
0.88
10.48
Earnings Yield (Greenblatt) % 1.41
VASC's Earnings Yield (Greenblatt) % is ranked higher than
59% of the 339 Companies
in the Global Medical Devices industry.

( Industry Median: -0.81 vs. VASC: 1.41 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
VASC' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.5  Med: 5.25 Max: 10.3
Current: 1.41
0.5
10.3
Forward Rate of Return (Yacktman) % 0.77
VASC's Forward Rate of Return (Yacktman) % is ranked lower than
73% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 9.01 vs. VASC: 0.77 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
VASC' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -9.7  Med: 2.6 Max: 54.1
Current: 0.77
-9.7
54.1

More Statistics

Revenue (TTM) (Mil) $160.4
EPS (TTM) $ 0.70
Beta1.04
Short Percentage of Float1.36%
52-Week Range $25.06 - 57.15
Shares Outstanding (Mil)17.57

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 166 187
EPS ($) 1.23 1.47 1.72
EPS without NRI ($) 1.23 1.47 1.72
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for VASC

Headlines

Articles On GuruFocus.com
Mario Gabelli Comments on Vascular Solutions Jan 31 2017 
Mairs & Power Comments on Vascular Solutions Dec 01 2015 
Vascular Solutions Inc. Reports Operating Results (10-K) Feb 01 2011 
Vascular Solutions Inc. (VASC) CEO Howard Root sells 25,000 Shares Nov 04 2010 
Vascular Solutions Inc. Reports Operating Results (10-K) Feb 02 2010 
Vascular Solutions Inc. Reports Operating Results (10-Q) Apr 17 2009 

More From Other Websites
VASCULAR SOLUTIONS INC Files SEC form 8-K, Termination of a Material Definitive Agreement,... Feb 21 2017
VASCULAR SOLUTIONS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders,... Feb 16 2017
Vascular Solutions Shareholders Approve Acquisition by Teleflex Feb 16 2017
Progenics Pharmaceuticals and Shutterfly to Join S&P SmallCap 600 Feb 15 2017
[$$] Mario Gabelli's Latest Big Buy: Vascular Solutions Feb 03 2017
VASCULAR SOLUTIONS INC Files SEC form 8-K, Other Events Jan 31 2017
Mario Gabelli Comments on Vascular Solutions Jan 31 2017
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Vascular Solutions, Inc.... Jan 18 2017
Lifshitz & Miller Law Firm Announces Investigation of Calamos Asset Management, Inc., CDI Corp.,... Jan 17 2017
INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Vascular... Dec 16 2016
Hedge Funds Are Crazy About Vascular Solutions, Inc. (VASC) Dec 16 2016
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of... Dec 15 2016
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Vascular... Dec 13 2016
Vascular Solutions, Inc. Acquisition May Not Be in the Best Interests of VASC Shareholders Dec 13 2016
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of... Dec 13 2016
VASCULAR SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Vascular Solutions,... Dec 09 2016
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of... Dec 07 2016
Hedge Funds Continue to Hold On To Quality Systems, Inc. (QSII) Dec 05 2016
VASCULAR SOLUTIONS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP... Dec 05 2016
Ryan & Maniskas, LLP Announces Investigation of Vascular Solutions, Inc. Dec 05 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)